Celgene, MorphoSys sign antibody drug deal worth up to $818M

Celgene and MorphoSys will collaborate in the development of the latter's fully human monoclonal antibody MOR202 for treatment of multiple myeloma and other indications in a deal worth as much as $818 million. The drug, which targets the CD38 protein, is in a Phase I/IIa study against relapsed/refractory melanoma. MorphoSys will get $92 million upfront and a $60 million investment from Celgene, in addition to possible milestone fees and sales royalties.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC